Most (18/27, 67%) had a CSF AD biomarker profile consistent with AD, as defined by an amyloid‐positive, p‐tau‐positive (A+T+) profile, categorized using established cut‐offs, as described in our previous study.10 This evidence concerns the gene MAPT and Alzheimer disease.